CN113966325A - 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用 - Google Patents

含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用 Download PDF

Info

Publication number
CN113966325A
CN113966325A CN202080033678.3A CN202080033678A CN113966325A CN 113966325 A CN113966325 A CN 113966325A CN 202080033678 A CN202080033678 A CN 202080033678A CN 113966325 A CN113966325 A CN 113966325A
Authority
CN
China
Prior art keywords
ion
alkyl
hydrogen
compound
fluorine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080033678.3A
Other languages
English (en)
Other versions
CN113966325B (zh
Inventor
邓贤明
林圣彩
张宸崧
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiamen Huachuo Biomedical Technology Co ltd
Original Assignee
Xiamen Huachuo Biomedical Technology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiamen Huachuo Biomedical Technology Co ltd filed Critical Xiamen Huachuo Biomedical Technology Co ltd
Publication of CN113966325A publication Critical patent/CN113966325A/zh
Application granted granted Critical
Publication of CN113966325B publication Critical patent/CN113966325B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/68—Halogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/60—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with hydrocarbon radicals, substituted by oxygen or sulfur atoms, attached to ring nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一类具有激活5’‑腺苷一磷酸活化的蛋白激酶(AMPK)活性的化合物，其制备方法、包含该化合物的药物组合物，以及这些化合物在制备用于降低脂肪酸合成的药物、抑制甘油三酯和胆固醇合成的药物、预防和/或治疗肥胖以及II型糖尿病的药物、预防和/或治疗肿瘤的药物、预防和/或治疗帕金森症的药物、预防和/或治疗阿尔茨海默症的药物或者延长哺乳动物寿命的药物中的用途：
Figure DDA0003338047060000011

Description

PCT国内申请，说明书已公开。

Claims (7)

  1. PCT国内申请，权利要求书已公开。
CN202080033678.3A 2019-05-10 2020-05-08 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用 Active CN113966325B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201910387619.5A CN111909092A (zh) 2019-05-10 2019-05-10 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用
CN2019103876195 2019-05-10
PCT/CN2020/089128 WO2020228596A1 (zh) 2019-05-10 2020-05-08 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用

Publications (2)

Publication Number Publication Date
CN113966325A true CN113966325A (zh) 2022-01-21
CN113966325B CN113966325B (zh) 2023-10-03

Family

ID=73242843

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910387619.5A Pending CN111909092A (zh) 2019-05-10 2019-05-10 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用
CN202080033678.3A Active CN113966325B (zh) 2019-05-10 2020-05-08 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201910387619.5A Pending CN111909092A (zh) 2019-05-10 2019-05-10 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用

Country Status (7)

Country Link
US (1) US20220242828A1 (zh)
EP (1) EP3967683A4 (zh)
JP (1) JP2022532006A (zh)
CN (2) CN111909092A (zh)
AU (1) AU2020274362B2 (zh)
CA (1) CA3140417A1 (zh)
WO (1) WO2020228596A1 (zh)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133923A1 (ja) * 2008-04-30 2009-11-05 石原産業株式会社 1,2,3－置換イミダゾリウム塩を有効成分として含有する農園芸用殺菌剤
CN101983057A (zh) * 2008-01-30 2011-03-02 新加坡科技研究局 用咪唑和咪唑啉化合物治疗纤维变性和癌症的方法
CN103547154A (zh) * 2011-04-29 2014-01-29 阿克伦大学 唑鎓和嘌呤鎓盐抗癌及抗微生物剂
WO2018184561A1 (zh) * 2017-04-07 2018-10-11 厦门华绰生物医药科技有限公司 取代咪唑盐类化合物、其制备方法、药用组合物及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563657B2 (en) * 2008-04-04 2013-10-22 The Research Foundation Of State University Of New York Ionic liquids, functionalized particulates, and fluoropolymer composites

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101983057A (zh) * 2008-01-30 2011-03-02 新加坡科技研究局 用咪唑和咪唑啉化合物治疗纤维变性和癌症的方法
WO2009133923A1 (ja) * 2008-04-30 2009-11-05 石原産業株式会社 1,2,3－置換イミダゾリウム塩を有効成分として含有する農園芸用殺菌剤
CN103547154A (zh) * 2011-04-29 2014-01-29 阿克伦大学 唑鎓和嘌呤鎓盐抗癌及抗微生物剂
WO2018184561A1 (zh) * 2017-04-07 2018-10-11 厦门华绰生物医药科技有限公司 取代咪唑盐类化合物、其制备方法、药用组合物及其应用
CN108689939A (zh) * 2017-04-07 2018-10-23 厦门华绰生物医药科技有限公司 取代咪唑盐类化合物、其制备方法、药用组合物及其应用

Also Published As

Publication number Publication date
US20220242828A1 (en) 2022-08-04
KR20220004730A (ko) 2022-01-11
JP2022532006A (ja) 2022-07-13
CN113966325B (zh) 2023-10-03
AU2020274362B2 (en) 2023-07-13
EP3967683A4 (en) 2023-05-31
WO2020228596A8 (zh) 2021-12-16
WO2020228596A1 (zh) 2020-11-19
TW202104192A (zh) 2021-02-01
CA3140417A1 (en) 2020-11-19
EP3967683A1 (en) 2022-03-16
AU2020274362A1 (en) 2021-12-23
CN111909092A (zh) 2020-11-10

Similar Documents

Publication Publication Date Title
CN113194958B (zh) THRβ受体激动剂化合物及其制备方法和用途
WO2016041489A1 (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
KR20150003875A (ko) 바독솔론 메틸의 2,2-다이플루오로프로피온아미드 유도체, 그의 다형태 및 사용 방법
US20230202986A1 (en) Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof
EP1902054B1 (fr) Derives de pyrido[2,3-d]pyrimidine, leur preparation, leur application en therapeutique
HUE031506T2 (en) Aldose reductase inhibitors and their use
CN110698415B (zh) 一种肌球蛋白抑制剂及其制备方法和用途
WO2010130934A2 (fr) Derives de 2-cycloamino-5-(pyridin-4-yl)imidazo[2,1-b][1,3,4]thiadiazole, leur preparation et leur application en therapeutique
CN111918864A (zh) 通过akr1c3活化的前药化合物及其治疗过度增殖性失调的用途
CN111518101A (zh) 吡咯并嘧啶衍生物及其用途
CN110872285A (zh) 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物
JP7374233B2 (ja) 立体配置を有するチエノピリミジン誘導体及び薬物におけるその応用
EP2419422A1 (fr) Dérivés d'imidazolidine-2,4-dione et leur utilisation comme médicament
WO2020228596A1 (zh) 含氟取代咪唑盐类化合物、其制备方法、药用组合物及其应用
KR102683706B1 (ko) 치환된 불소-함유 이미다졸 염 화합물, 이의 제조 방법, 이의 약학적 조성물 및 이의 용도
US9682954B2 (en) Phenanthridine derivatives, preparation methods and uses thereof
JP2020518563A (ja) 抗ガン幹細胞性薬物
JP2020502283A (ja) インドールアミン−２，３−ジオキシゲナーゼ阻害剤としてのスルホニルアミディーン及びその製造方法と用途
CN112209896B (zh) 噻唑烷二酮衍生物以及包含其的药物组合物
CN109748914B (zh) 吡啶并嘧啶类化合物及其应用
TWI845673B (zh) 含氟取代咪唑鹽類化合物、其製備方法、藥用組合物及其應用
JPH02169571A (ja) 置換アリルアミン誘導体
US3801578A (en) 7-(2-hydroxy-3-(n-methyl-2-hydroxy-ethylamino)-propyl)-theophylline-2-(4-chlorophenoxy)-isobutyrate
JP2023518299A (ja) 小分子エナンチオマーによるアンドロゲン受容体調節
JPH05213923A (ja) 新規なチオアミド誘導体またはその塩

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant